July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb
Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in combinations for all indications. The deal covers Japan, South Korea,

Read the full 442 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE